Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 136.90
SRPT's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 136.90 )
SRPT' s 10-Year Cash to Debt Range
Min: 4.43   Max: No Debt
Current: 136.9

Equity to Asset 0.83
SRPT's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 0.83 )
SRPT' s 10-Year Equity to Asset Range
Min: -0.09   Max: 0.98
Current: 0.83

-0.09
0.98
F-Score: 4
Z-Score: 7.67
M-Score: -1.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -634.95
SRPT's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -634.95 )
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87   Max: -71.16
Current: -634.95

-28680.87
-71.16
Net-margin (%) -787.57
SRPT's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -787.57 )
SRPT' s 10-Year Net-margin (%) Range
Min: -27020   Max: -4.93
Current: -787.57

-27020
-4.93
ROE (%) -45.30
SRPT's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -45.30 )
SRPT' s 10-Year ROE (%) Range
Min: -296.67   Max: -7.47
Current: -45.3

-296.67
-7.47
ROA (%) -38.41
SRPT's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -38.41 )
SRPT' s 10-Year ROA (%) Range
Min: -261.76   Max: -4.26
Current: -38.41

-261.76
-4.26
ROC (Joel Greenblatt) (%) -599.93
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -599.93 )
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075   Max: -269.31
Current: -599.93

-2075
-269.31
Revenue Growth (%) -35.80
SRPT's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -35.80 )
SRPT' s 10-Year Revenue Growth (%) Range
Min: -63.2   Max: 383.5
Current: -35.8

-63.2
383.5
EBITDA Growth (%) 35.80
SRPT's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 35.80 )
SRPT' s 10-Year EBITDA Growth (%) Range
Min: -36.3   Max: 43.4
Current: 35.8

-36.3
43.4
EPS Growth (%) 23.90
SRPT's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 23.90 )
SRPT' s 10-Year EPS Growth (%) Range
Min: -62.4   Max: 46.9
Current: 23.9

-62.4
46.9
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SRPT Guru Trades in Q2 2013

George Soros 425,689 sh (+2.99%)
Columbia Wanger 1,787,000 sh (unchged)
Tom Russo Sold Out
Andreas Halvorsen 668,175 sh (-3.27%)
Steven Cohen 50,100 sh (-90.55%)
» More
Q3 2013

SRPT Guru Trades in Q3 2013

Steven Cohen 960,300 sh (+1816.77%)
George Soros 665,274 sh (+56.28%)
Andreas Halvorsen Sold Out
Columbia Wanger 1,431,000 sh (-19.92%)
» More
Q4 2013

SRPT Guru Trades in Q4 2013

Columbia Wanger 2,635,000 sh (+84.14%)
Steven Cohen 711,777 sh (-25.88%)
George Soros 233,000 sh (-64.98%)
» More
Q1 2014

SRPT Guru Trades in Q1 2014

Columbia Wanger 2,633,000 sh (-0.08%)
Steven Cohen 641,600 sh (-9.86%)
George Soros 25,000 sh (-89.27%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 Reduce -89.27%0.04%$17.91 - $30.29 $ 20.33-20%25000
George Soros 2013-12-31 Reduce -64.98%0.22%$12.89 - $53.81 $ 20.33-31%233000
George Soros 2013-09-30 Add 56.28%0.12%$30.906 - $47.97 $ 20.33-47%665274
George Soros 2013-03-31 Add 82.54%0.08%$23.97 - $36.95 $ 20.33-30%413329
George Soros 2012-12-31 Add 184.13%0.05%$14.99 - $44.93 $ 20.33-24%226429
Jean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6 $ 20.33236%0
Jean-Marie Eveillard 2011-12-31 Reduce -83.33%$3.24 - $6.54 $ 20.33303%50000
Jean-Marie Eveillard 2011-09-30 Add 50%$6.3 - $9.9 $ 20.33157%300000
Jean-Marie Eveillard 2011-06-30 New Buy$8.1 - $11.22 $ 20.33110%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.40
SRPT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.40 )
SRPT' s 10-Year P/B Range
Min: 1.61   Max: 234
Current: 3.4

1.61
234
P/S 45.45
SRPT's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 45.45 )
SRPT' s 10-Year P/S Range
Min: 1.56   Max: 310
Current: 45.45

1.56
310
EV-to-EBIT -5.71
SRPT's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -5.71 )
SRPT' s 10-Year EV-to-EBIT Range
Min: 8   Max: 49.3
Current: -5.71

8
49.3
Current Ratio 6.60
SRPT's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 6.60 )
SRPT' s 10-Year Current Ratio Range
Min: 0.76   Max: 36.25
Current: 6.6

0.76
36.25
Quick Ratio 6.60
SRPT's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 6.60 )
SRPT' s 10-Year Quick Ratio Range
Min: 0.76   Max: 36.25
Current: 6.6

0.76
36.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.30
SRPT's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 4.30 )
SRPT' s 10-Year Price/Net Cash Range
Min: 3.01   Max: 72.6
Current: 4.3

3.01
72.6
Price/Net Current Asset Value 4.20
SRPT's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 4.20 )
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.96   Max: 115.5
Current: 4.2

2.96
115.5
Price/Tangible Book 3.50
SRPT's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.50 )
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 474
Current: 3.5

2.41
474
Price/Median PS Value 1.90
SRPT's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 1.90 )
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 76.32
Current: 1.9

0.08
76.32
Forward Rate of Return (Yacktman) 13.80
SRPT's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 13.80 )
SRPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.2   Max: 18.1
Current: 13.8

1.2
18.1

Business Description

Industry: »
Compare: » details
Traded in other countries:AB3A.Germany
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide